ALZN FY2025 SEC EDGAR DEF 14A #152 of 168 in industry

Alzamend Neuro, Inc. CEO pay ratio

The CEO earned $130K in FY2025 against median worker pay of $130,000 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-02-26
Industry
Chemicals & Pharmaceuticals
Industry rank
#152/168

Data updated August 2026

Subscribe to Alzamend Neuro, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
6:1
Below Average (Scale: 0–1000:1)
CEO pay
$130K
Median worker
$130,000

Answer first

Alzamend Neuro, Inc.'s FY2025 CEO total of $130K ranks #1368 of 1,423 complete filings; its 6:1 pay ratio ranks #1340. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $130,000. Industry placement uses the FY2025 SIC-28 peer cohort (# 152 of 168, 10th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1368
$130K of 1,423 FY2025
Ratio rank
#1340
6:1 of 1,423
Industry pct
10th
among the lower quartile of industry peers by pay ratio

How Alzamend Neuro, Inc. ranks nationally

Alzamend Neuro, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$130,000 4th percentile higher than 4% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Alzamend Neuro, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($130K) against pay ratio (6:1) for Alzamend Neuro, Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both06105785.612211571.218317356.724423142.33.1:113.3:123.5:133.7:143.9:1CEO total payPay ratio (CEO : median worker)Alzamend Neuro, Inc., CEO total pay: 130000 · Pay ratio (CEO : median worker): 6:1Alzamend Neuro, Inc.Edgewise Therapeutics, Inc., CEO total pay: 443614 · Pay ratio (CEO : median worker): 6:1Edgewise Therapeutics, Inc.Dyne Therapeutics, Inc., CEO total pay: 2031900 · Pay ratio (CEO : median worker): 6:1Dyne Therapeutics, Inc.Ptc Therapeutics, Inc., CEO total pay: 23266326 · Pay ratio (CEO : median worker): 7:1Ptc Therapeutics, Inc.Celanese Corp, CEO total pay: 462700 · Pay ratio (CEO : median worker): 5:1Celanese Corp
Alzamend Neuro, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Alzamend Neuro, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Alzamend Neuro, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2023–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
6:1
FY2025
vs prior FY
+3:1
from FY2024 3:1
CEO $ YoY
0%
$130K latest
Filings shown
3
FY2023–2025
Alzamend Neuro, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2023 $130K - $130,000 17:1 -
2024 $130K 0% $130,000 3:1 -14:1
2025 $130K 0% $130,000 6:1 +3:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1677077, FY2023–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
6:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$130K
Companies in Industry
168
vs. Industry Median
Below
#152 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Alzamend Neuro, Inc.: near-parity Item 402(u) ratio

Alzamend Neuro, Inc.'s FY2025 ratio 6:1 ranks #152 of 168 Chemicals & Pharmaceuticals filers (10th percentile). the CEO earned 6× the median employee ($130,000) in FY2025.

At $130,000 median worker pay, the FLOOR stamp is near pay-parity territory under MICRO CEO total.

CEO Total Pay

$130K

FY2025 Summary Compensation, below median

Pay Ratio

6:1

Below typical

Alzamend Neuro, Inc. in the lower Chemicals & Pharmaceuticals third

Alzamend Neuro, Inc.'s FY2025 ratio 6:1 ranks #152 of 168 Chemicals & Pharmaceuticals filers (10th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Alzamend Neuro, Inc.'s $130K CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1368 and ratio rank #1340 split - treat 6:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$130K
Median Employee Pay
$130,000
Pay Ratio
6:1
Filing Date
2026-02-26

Company Info

Ticker
ALZN
CIK
1677077
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1677077, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Alzamend Neuro, Inc.'s FY2025 ratio 6:1 ranks #152 of 168 Chemicals & Pharmaceuticals filers (10th percentile).

Read with Alzamend Neuro, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MICRO · ELITE-MED.

Delek US Holdings, Inc. · MICRO

ABS(ceo_total_comp) peer at $130K (Δ $26 lighter vs Alzamend Neuro, Inc.); MODEST · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Centerpoint Energy Inc · MICRO

ABS(ceo_total_comp) peer at $130K (Δ $189 heavier vs Alzamend Neuro, Inc.); MID · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Rb Global Inc. · MICRO

ABS(ceo_total_comp) peer at $130K (Δ $430 lighter vs Alzamend Neuro, Inc.); PARITY · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Emergent BioSolutions Inc. · MICRO

ABS(ceo_total_comp) peer at $131K (Δ $553 heavier vs Alzamend Neuro, Inc.); MODEST · LOW-MED vs this page's FLOOR · MICRO · ELITE-MED.
Edgewise Therapeutics, Inc. (SIC 28 pole)

Edgewise Therapeutics, Inc. stamps FLOOR · MICRO nearest in-SIC by ABS(pay_ratio) to Alzamend Neuro, Inc.'s FLOOR filing.
National dual ranks · #1368/#1340

Alzamend Neuro, Inc.'s FY2025 package sits #1368 by CEO dollars and #1340 by ratio under MICRO · FLOOR.
Ratio primer · FLOOR

Alzamend Neuro, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Alzamend Neuro, Inc. (CIK 1677077), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.